No Significant Changes of Glycemic Control and Renal Function in Patients with Advanced-Stage Diabetic Kidney Disease by Switching from Linagliptin to Teneligliptin

Figures & data

Figure 1 Study design.

Abbreviations: eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; UACR, urine albumin-to-creatinine ratio.

Table 1 Baseline Patient Characteristics

	Teneligliptin Group (n = 13)	Linagliptin Group (n = 13)	P value
Age (years)	74.8 ± 8.3	68.6 ± 11.5	0.13
Sex (male/female)	7/6	7/6	1.00
Body mass index (kg/m^2)	25.2 ± 3.3	24.3 ± 3.0	0.44
Systolic blood pressure (mmHg)	138.3 ± 9.1	135.5 ± 19.3	0.64
Diastolic blood pressure (mmHg)	73.9 ± 11.2	70.4 ± 12.0	0.44
Serum creatinine (mg/dL)	2.4 ± 1.0	2.1 ± 1.0	0.42
eGFR (mL/min/1.73m^2)	22.6 ± 9.4	25.8 ± 8.9	0.47
CKD stage (number, %)
G3b	3 (23.1)	4 (30.8)	0.75
G4	7 (53.8)	6 (46.2)
G5	3 (23.1)	3 (23.1)
Urinary protein excretion (g/gCr)	1.0 ± 1.1	1.7 ± 1.6	0.32
History of underlying causes of CKD (number, %)
Diabetic nephropathy	8 (61.5)	9 (69.2)	0.72
Hypertensive nephrosclerosis	2 (15.4)	3 (23.1)
Chronic glomerulonephritis	3 (23.1)	1 (7.7)
Duration of diabetes mellitus (year)	17.5 ± 12.8	24.3 ± 11.9	0.18
HbA1c (%)	6.8 ± 0.7	7.1 ± 0.6	0.26
Fasting blood glucose (mg/dL)	132.6 ± 28.8	146.4 ± 31.0	0.30
LDL-cholesterol (mg/dL)	88.5 ± 21.7	96.4 ± 28.7	0.44
HDL-cholesterol (mg/dL)	44.9 ± 15.2	41.9 ± 15.5	0.62
Triglyceride (mg/dL)	194.6 ± 113.1	145.2 ± 83.5	0.22
Uric acid (mg/dL)	5.8 ± 1.3	5.8 ± 1.4	0.95
Albumin (g/dL)	4.0 ± 0.4	3.9 ± 0.4	0.69
Hemoglobin (g/dL)	11.8 ± 1.9	11.6 ± 1.9	0.85
Erythropoiesis-stimulating agent (number, %)	3 (23.1)	4 (30.8)	1.00
Glinide (number, %)	3 (23.1)	5 (38.5)	0.67
α-glucosidase inhibitor (number, %)	1 (7.7)	1 (7.7)	1.00
SGLT2 inhibitor (number, %)	1 (7.7)	2 (15.4)	1.00
Insulin (number, %)	3 (23.1)	4 (30.8)	1.00
RAS blocker (number, %)	9 (69.2)	10 (76.9)	1.00
Diuretic (number, %)	7 (53.8)	4 (30.8)	0.43
Statin (number, %)	9 (69.2)	6 (46.2)	0.43
Eicosapentaenoic acid (number, %)	3 (23.1)	3 (23.1)	1.00
Antiplatelet agent (number, %)	6 (46.2)	8 (61.5)	0.70
Antihyperuricemic drug (number, %)	11 (84.6)	9 (69.2)	0.64

Note: Data are presented as mean ± standard deviation, number, or number (%).

Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RAS, renin–angiotensin system; SGLT-2, sodium–glucose cotransporter-2.

Figure 2 Patient flow diagram.

Abbreviations: eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio.

Figure 3 Changes in HbA1c over 12 months following the baseline measurement. (A) Changes in HbA1c in the teneligliptin and linagliptin groups. (B) Changes in HbA1c in the teneligliptin group. Eleven patients were taking 20 mg/day of teneligliptin (thin solid line) and two patients were 40 mg/day (bold solid line). (C) Changes in HbA1c in the linagliptin group.

Abbreviations: HbA1c, glycated hemoglobin; NS, not significant.

Figure 4 Changes in FBG over 12 months following the baseline measurement. (A) Changes in FBG in the teneligliptin and linagliptin groups. (B) Changes in FBG in the teneligliptin group. Eleven patients were taking 20 mg/day of teneligliptin (thin solid line) and two patients were 40 mg/day (bold solid line). (C) Changes in FBG in the linagliptin group.

Abbreviations: FBG, fasting blood glucose; NS, not significant.

Figure 5 Changes in UACR over 12 months following the baseline measurement. (A) Changes in UACR in the teneligliptin and linagliptin groups. (B) Changes in UACR in the teneligliptin group. Eleven patients were taking 20 mg/day of teneligliptin (thin solid line) and two patients were 40 mg/day (bold solid line). (C) Changes in UACR in the linagliptin group.

Abbreviations: NS, not significant; UACR, urine albumin-to-creatinine ratio.

Figure 6 Changes in eGFR over 12 months before and after the baseline measurement. (A) Changes in eGFR in the teneligliptin and linagliptin groups. (B) Changes in eGFR in the teneligliptin group. Eleven patients were taking 20 mg/day of teneligliptin (thin solid line) and two patients were 40 mg/day (bold solid line). (C) Changes in eGFR in the linagliptin group.

Abbreviation: eGFR, estimated glomerular filtration rate.

Figure 7 Annual changes in eGFR before and after baseline in the teneligliptin and linagliptin groups.

Abbreviations: eGFR, estimated glomerular filtration rate; NS, not significant.